Phil Blog

Phil Blog

Translating Data into Actionable Insights to Inform your Patient Access Strategy

By Andrew Duncan, SVP of Business Operations, Pricing & Strategic Finance Pharmaceutical companies are embracing big data initiatives to drive their business objectives. For brand teams, data is valuable only when they have the right data to make informed decisions that improve access to their retail and specialty-lite therapies. Life science companies that invest in capabilities to capture, strategically analyze, and draw actionable insights from the most relevant data will realize better brand outcomes

Meet Johnny Yu, VP of Patient Experience at Phil

Next up in our Employee Spotlight series is Johnny Yu, VP of Patient Experience. Learn how Johnny’s enthusiasm, team-building skills, and drive to achieve the best patient experience make him a valuable asset at Phil. Please tell us a little bit about yourself and your role at Phil

Proactive Steps to Overcoming the Top 3 Patient Access Barriers to Retail and Specialty-Lite Therapies

Ensuring patients get started and adhere to their medications is critical to achieving optimal health outcomes. However, navigating the medication access journey is no longer straightforward. An estimated 1 out of 4 prescriptions are abandoned at the pharmacy, and a recent report found that more than 8 out of 10 patients encounter delays in accessing the medications they need to manage their health

Meet Nicole Grycan, VP Commercialization at Phil

We are thrilled to have our VP of Commercialization, Nicole Grycan, share her personal journey with us in our next employee spotlight. Nicole’s industry expertise is instrumental in our mission to help people get their medications quickly, easily, and affordably. Tell me a little bit about yourself and what you do at Phil

How Drug Manufacturers Can Evolve their Provider Engagement Model to Drive Brand Performance

Evolving healthcare provider (HCP) needs and expectations have disrupted conventional customer engagement methods. The traditional reach and frequency model that had long been successful for pharma companies no longer delivers on brand goals. Several factors are driving this change